Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Leap Therapeutics in reverse merger

by Ann M. Thayer
September 5, 2016 | A version of this story appeared in Volume 94, Issue 35

Trying to raise capital in a down period for initial public stock offerings, Leap Therapeutics will conduct a reverse merger with publicly held Macrocure. As a result, Leap’s stock will be traded and Macrocure will become a subsidiary. The deal should give Leap $30 million to support development of its immuno-oncology antibodies. A week earlier, the regenerative medicine firm BioCardia agreed to do a reverse merger with Tiger X Medical. And PixarBio, a pain management company cofounded by MIT professor Robert Langer, is in the process of reverse merging with an undisclosed public firm.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.